Krystal Biotech Quarterly Income Statements Chart
Quarterly
|
Annual
Krystal Biotech Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| product revenue | 96,042,000 | 88,183,000 | 91,139,000 | 83,841,000 | 70,284,000 | 45,250,000 | 42,143,000 | 8,556,000 | ||||||||||||||||||||||||
| yoy | 36.65% | 94.88% | 116.26% | 879.91% | ||||||||||||||||||||||||||||
| qoq | 8.91% | -3.24% | 8.70% | 19.29% | 55.32% | 7.37% | 392.55% | |||||||||||||||||||||||||
| operating expenses | ||||||||||||||||||||||||||||||||
| cost of goods sold | 7,165,000 | 5,028,000 | 4,949,000 | 6,684,000 | 6,009,000 | 2,419,000 | 2,871,000 | 223,000 | ||||||||||||||||||||||||
| research and development | 14,410,000 | 14,255,000 | 13,523,000 | 13,511,000 | 15,583,000 | 10,957,000 | 11,370,000 | 10,629,000 | 12,144,000 | 12,288,000 | 10,741,000 | 11,516,000 | 10,890,000 | 9,314,000 | 9,009,000 | 6,080,000 | 6,594,000 | 6,201,000 | 5,672,000 | 5,100,000 | 3,639,000 | 3,525,000 | 4,349,000 | 3,885,000 | 4,216,000 | 3,167,000 | 2,802,000 | 1,914,000 | 1,525,000 | 1,520,000 | 1,088,000 | 1,355,000 |
| selling, general and administrative | 35,160,000 | 32,723,000 | 31,288,000 | 28,713,000 | 27,626,000 | |||||||||||||||||||||||||||
| litigation settlement | 12,500,000 | 12,500,000 | 12,500,000 | 12,500,000 | 25,000,000 | |||||||||||||||||||||||||||
| total operating expenses | 56,735,000 | 52,006,000 | 49,760,000 | 61,408,000 | 61,718,000 | 51,934,000 | 39,005,000 | 34,549,000 | 38,048,000 | 48,823,000 | 34,771,000 | 31,451,000 | 28,753,000 | 50,222,000 | 21,876,000 | 15,652,000 | 16,393,000 | 14,353,000 | 10,420,000 | 9,680,000 | 6,954,000 | 5,946,000 | 6,154,000 | 5,342,000 | 5,890,000 | 4,694,000 | 4,219,000 | 2,972,000 | 2,449,000 | 2,277,000 | 1,498,000 | 2,093,000 |
| income from operations | 39,307,000 | 36,177,000 | 41,379,000 | 22,433,000 | 8,566,000 | -6,684,000 | 3,138,000 | -25,993,000 | -38,048,000 | -48,823,000 | -34,771,000 | -31,451,000 | -28,753,000 | -50,222,000 | -21,876,000 | -15,652,000 | -16,393,000 | -14,353,000 | -10,420,000 | -9,680,000 | -6,954,000 | -5,946,000 | -6,154,000 | -5,342,000 | -5,890,000 | -4,694,000 | -4,219,000 | -2,972,000 | -2,449,000 | -2,277,000 | -1,498,000 | -2,093,000 |
| yoy | 358.87% | -641.25% | 1218.64% | -186.30% | -122.51% | -86.31% | -109.02% | -17.35% | 32.33% | -2.79% | 58.95% | 100.94% | 75.40% | 249.91% | 109.94% | 61.69% | 135.73% | 141.39% | 69.32% | 81.21% | 18.06% | 26.67% | 45.86% | 79.74% | 140.51% | 106.15% | 181.64% | 42.00% | ||||
| qoq | 8.65% | -12.57% | 84.46% | 161.88% | -228.16% | -313.00% | -112.07% | -31.68% | -22.07% | 40.41% | 10.56% | 9.38% | -42.75% | 129.58% | 39.76% | -4.52% | 14.21% | 37.74% | 7.64% | 39.20% | 16.95% | -3.38% | 15.20% | -9.30% | 25.48% | 11.26% | 41.96% | 21.36% | 7.55% | 52.00% | -28.43% | |
| operating margin % | 40.93% | 41.02% | 45.40% | 26.76% | 12.19% | -14.77% | 7.45% | -303.80% | ||||||||||||||||||||||||
| other income | ||||||||||||||||||||||||||||||||
| interest and other income | 7,468,000 | 7,420,000 | 7,231,000 | 7,336,000 | 7,479,000 | 7,616,000 | 7,519,000 | 6,740,000 | 4,838,000 | 3,526,000 | 2,719,000 | 1,601,000 | 645,000 | 257,000 | 70,000 | 63,000 | 30,000 | 33,000 | 37,000 | 70,000 | 121,000 | 605,000 | 797,000 | 1,070,000 | 542,000 | 583,000 | 511,000 | 217,000 | 173,000 | 127,000 | ||
| income before income taxes | 46,775,000 | 43,597,000 | 48,610,000 | 29,769,000 | 16,045,000 | |||||||||||||||||||||||||||
| income tax expense | -8,442,000 | -7,864,000 | -3,131,000 | -2,589,000 | -477,000 | |||||||||||||||||||||||||||
| net income | 38,333,000 | 35,733,000 | 45,479,000 | 27,180,000 | 15,568,000 | 932,000 | 8,692,000 | 80,747,000 | -33,210,000 | -45,297,000 | -32,052,000 | -29,850,000 | -28,108,000 | -49,965,000 | -21,806,000 | -15,589,000 | -16,363,000 | -15,812,000 | -10,383,000 | -9,610,000 | -6,833,000 | -5,341,000 | -5,357,000 | -4,272,000 | -5,348,000 | -4,111,000 | -2,150,000 | -1,393,000 | -5,273,000 | |||
| yoy | 146.23% | 3734.01% | 423.23% | -66.34% | -146.88% | -102.06% | -127.12% | -370.51% | 18.15% | -9.34% | 46.99% | 91.48% | 71.78% | 215.99% | 110.02% | 62.22% | 139.47% | 196.05% | 93.82% | 124.95% | 27.77% | 29.92% | 91.21% | |||||||||
| qoq | 7.28% | -21.43% | 67.33% | 74.59% | 1570.39% | -89.28% | -89.24% | -343.14% | -26.68% | 41.32% | 7.38% | 6.20% | -43.74% | 129.13% | 39.88% | -4.73% | 3.48% | 52.29% | 8.04% | 40.64% | 27.93% | -0.30% | 25.40% | -20.12% | 30.09% | 54.34% | -73.58% | |||||
| net income margin % | 39.91% | 40.52% | 49.90% | 32.42% | 22.15% | 2.06% | 20.63% | 943.75% | ||||||||||||||||||||||||
| unrealized gain on available-for-sale securities | -158,000 | -5,000 | 7,000 | -24,000 | -3,000 | -14,000 | -20,000 | 16,000 | 14,000 | -1,000 | -7,000 | 2,000 | 14,000 | 1,000 | 3,000 | |||||||||||||||||
| foreign currency translation | 925,000 | |||||||||||||||||||||||||||||||
| comprehensive income | 39,100,000 | 36,313,000 | 43,777,000 | 29,326,000 | 15,233,000 | -5,000 | 9,712,000 | 80,601,000 | -33,292,000 | -44,723,000 | -31,305,000 | -29,780,000 | -28,456,000 | -50,999,000 | -21,955,000 | -15,582,000 | -16,387,000 | -15,815,000 | -10,397,000 | -9,630,000 | -6,817,000 | -5,327,000 | -5,358,000 | -4,279,000 | -5,346,000 | -4,097,000 | -3,707,000 | -2,752,000 | -2,278,000 | |||
| net income per common share: | ||||||||||||||||||||||||||||||||
| basic | 1,330 | 1,240 | 1,590 | 950 | 540 | 30 | 320 | 2,880 | ||||||||||||||||||||||||
| diluted | 1,290 | 1,200 | 1,530 | 910 | 530 | 30 | 310 | 2,790 | ||||||||||||||||||||||||
| weighted-average common shares outstanding: | 26,656,883,000 | 25,712,220,000 | 25,491,721,000 | 25,619,125,000 | 25,545,167,000 | 25,114,453,000 | 22,196,846,000 | 22,212,266,000 | 22,204,659,000 | 21,253,508,000 | 18,787,161,000 | 19,676,016,000 | 18,383,941,000 | 17,359,356,000 | 15,901,083,000 | 17,291,245,000 | 14,522,515 | 14,417,649 | ||||||||||||||
| basic | 28,910,000 | 28,815,000 | 28,592,000 | 28,716,000 | 28,598,000 | 28,295,000 | 27,154,190,000 | 28,042,130,000 | ||||||||||||||||||||||||
| diluted | 29,749,000 | 29,871,000 | 29,740,000 | 29,902,000 | 29,637,000 | 29,291,000 | 27,751,809,000 | 28,892,226,000 | ||||||||||||||||||||||||
| unrealized gain on available-for-sale securities and other | 580,000 | 218,500 | 2,146,000 | -335,000 | -937,000 | |||||||||||||||||||||||||||
| expenses | ||||||||||||||||||||||||||||||||
| gain from sale of priority review voucher | 100,000,000 | |||||||||||||||||||||||||||||||
| selling, general, and administrative | 26,058,000 | 18,409,250 | 23,697,000 | |||||||||||||||||||||||||||||
| expenses: | ||||||||||||||||||||||||||||||||
| other income: | ||||||||||||||||||||||||||||||||
| unrealized gain on available-for-sale securities and currency translation adjustment | 86,500 | -146,000 | -82,000 | 574,000 | -328,000 | 70,000 | ||||||||||||||||||||||||||
| general and administrative | 25,904,000 | 24,035,000 | 24,030,000 | 19,935,000 | 17,863,000 | 15,908,000 | 12,867,000 | 9,572,000 | 9,799,000 | 8,152,000 | 4,748,000 | 4,580,000 | 3,315,000 | 2,421,000 | 1,805,000 | 1,457,000 | 1,674,000 | 1,527,000 | 1,417,000 | 1,058,000 | 924,000 | 757,000 | 410,000 | 738,000 | ||||||||
| net income per common share: basic and diluted | -1,250 | -1,760 | -1,250 | -1,170 | -1,100 | -1,990 | -950 | -700 | -740 | -740 | -530 | -490 | -370 | -310 | -310 | -250 | ||||||||||||||||
| weighted-average common shares outstanding: | 26,656,883,000 | 25,712,220,000 | 25,491,721,000 | 25,619,125,000 | 25,545,167,000 | 25,114,453,000 | 22,196,846,000 | 22,212,266,000 | 22,204,659,000 | 21,253,508,000 | 18,787,161,000 | 19,676,016,000 | 18,383,941,000 | 17,359,356,000 | 15,901,083,000 | 17,291,245,000 | 14,522,515 | 14,417,649 | ||||||||||||||
| interest expense | -1,492,000 | -813,250 | -3,180,000 | |||||||||||||||||||||||||||||
| unrealized loss on available-for-sale securities and currency translation adjustment | -348,000 | |||||||||||||||||||||||||||||||
| unrealized loss on available-for-sale securities and other | -1,034,000 | |||||||||||||||||||||||||||||||
| total interest and other income | 542,000 | 583,000 | 511,000 | 217,000 | 173,000 | 127,000 | ||||||||||||||||||||||||||
| net income attributable to common stockholders per share: basic and diluted | -0.37 | -0.29 | ||||||||||||||||||||||||||||||
| net income applicable to stockholders and members | -1,795,250 | -2,755,000 | -2,276,000 | -2,150,000 | -1,393,000 | -5,273,000 | ||||||||||||||||||||||||||
| net income attributable to common stockholders and members per share: basic and diluted | -0.173 | -0.26 | -0.22 | -0.21 | ||||||||||||||||||||||||||||
| weighted-average common shares and common units outstanding: basic and diluted | 11,203,081 | 10,624,113 | 10,310,101 | 10,307,379 | 5,360,536 | |||||||||||||||||||||||||||
| unrealized loss on available-for-sale securities | -2,000 | |||||||||||||||||||||||||||||||
| total other income | 105,000 | -3,180,000 | ||||||||||||||||||||||||||||||
| net income attributable to common stockholders per share: | ||||||||||||||||||||||||||||||||
| basic and diluted | -0.438 | -1.26 | ||||||||||||||||||||||||||||||
| weighted-average common shares and common units outstanding | ||||||||||||||||||||||||||||||||
| basic and diluted | 4,183,075 |
We provide you with 20 years income statements for Krystal Biotech stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Krystal Biotech stock. Explore the full financial landscape of Krystal Biotech stock with our expertly curated income statements.
The information provided in this report about Krystal Biotech stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.